Conformational antibodies targeted to misfolded SOD1 show promise not only as therapeutics for ALS, but also as valuable tools with which to probe the mechanisms of misfolded SOD1 toxicity. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.